- Matinas BioPharma ( NYSE: MTNB ) said it is collaborating with National Resilience to evaluate its lipid nanocrystal (LNC) platform delivery technology for certain nucleic acids.
- The companies signed a material transfer and evaluation agreement for exploring the potential for oral delivery of identified nucleic acids.
- The parties will work on a research program consisting of in vitro and in vivo testing of these nucleic acid formats in combination with Matinas' proprietary LNC platform.
- Terms of the collaboration were not disclosed.
- "Importantly, the nature of our collaboration and relationship with Resilience is distinct and different from our ongoing work with BioNTech, which allows us to pursue multiple potential applications for our LNC platform in the nucleic acid space simultaneously," said said Matinas Co-Founder and CEO Jerome Jabbour.
- Matinas noted that its LNC platform delivery technology offers the potential for next generation intracellular drug delivery beyond lipid nanoparticles and viral vectors with potential advantages across a range of therapeutics, including oral bioavailability.
- MTNB +6.20% to $0.56 premarket Jan. 12
For further details see:
Matinas stock rises on team up with National Resilience for drug delivery technology